{"gene":"CAD","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1998,"finding":"Caspase-3 cleaves ICAD (inhibitor of CAD/DFF40) at two specific sites, inactivating its CAD-inhibitory function and thereby releasing active CAD to mediate internucleosomal DNA degradation during apoptosis. Site-directed mutagenesis of both caspase-3 cleavage sites in ICAD blocked DNA degradation in Jurkat cells treated with Fas ligand or staurosporine, even though caspase activity was retained.","method":"Site-directed mutagenesis of ICAD caspase-3 cleavage sites; stable transfection of Jurkat cells; apoptosis induction assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis confirmed cleavage sites, functional rescue experiment in cells, replicated across multiple apoptotic stimuli","pmids":["9422513"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of activated CAD/DFF40 reveals it forms a homodimer with a deep active-site crevice suited for cleaving internucleosomal linker DNA. ICAD/DFF45 sequesters the nonfunctional CAD monomer and can also disassemble the active dimer via its middle domain; caspase cleavage of ICAD releases CAD to self-assemble into the active dimer.","method":"X-ray crystallography of activated CAD/DFF40; biochemical dimer assembly/disassembly assays","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure combined with biochemical validation of dimer assembly mechanism","pmids":["15149602"],"is_preprint":false},{"year":2000,"finding":"The N-terminal CAD domain of CAD/DFF40 adopts a ubiquitin superfold (one alpha-helix, five beta-strands) and binds tightly to the CAD domain of ICAD (Kd ~55 nM), indicating that this domain-domain interaction is critical for inhibition of DNase activity and for correct folding of CAD.","method":"Multi-dimensional NMR spectroscopy; surface plasmon resonance binding assay","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure determination plus quantitative binding measurement by SPR in single rigorous study","pmids":["10764577"],"is_preprint":false},{"year":2001,"finding":"CAD/DFF40 is essential for oligonucleosomal DNA fragmentation and final nuclear condensation/fragmentation during apoptosis, but is dispensable for high-molecular-weight DNA cleavage and early-stage chromatin condensation, demonstrating the existence of one or more separate nucleases responsible for those earlier events.","method":"Gene knockout (CAD−/− DT40 chicken cells with full ORF deletion); apoptosis induction assays; DNA gel electrophoresis; nuclear morphology analysis","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with specific phenotypic readouts, replicated across multiple apoptotic stimuli","pmids":["11577114"],"is_preprint":false},{"year":2001,"finding":"DFF40/CAD is a Mg2+-dependent endonuclease specific for double-stranded DNA that is optimally active at 50–125 mM K+ (matching apoptotic cytoplasmic ionic conditions), inhibited by Zn2+ and Cu2+, and active over pH 7.0–8.5. At high ionic strength the enzyme introduces single-strand nicks rather than double-strand breaks.","method":"In vitro endonuclease activity assays with purified DFF40/CAD across varying ionic conditions, divalent metals, and pH","journal":"Molecular and Cellular Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with systematic cofactor variation, single lab","pmids":["11330826"],"is_preprint":false},{"year":2008,"finding":"DFF40/CAD exclusively cleaves double-stranded DNA and does not cleave single-stranded DNA, RNA, double-stranded RNA, or RNA-DNA heteroduplexes; non-substrate nucleic acids act as competitive inhibitors of dsDNA cleavage, suggesting they bind the enzyme's DNA-binding site.","method":"In vitro nuclease assays with synthetic single- and double-stranded ribo- and deoxyribo-oligonucleotides; in vivo apoptosis RNA degradation correlation","journal":"Apoptosis","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic in vitro substrate specificity analysis with multiple substrate types, single lab","pmids":["18283539"],"is_preprint":false},{"year":2006,"finding":"DFF40/CAD is inhibited by polyanions including RNA, single-stranded DNA, poly-glutamic acid, and heparin (nanomolar potency); these polyanions bind to positively charged surfaces formed by the alpha-4 helices of the DFF40/CAD homodimer, impairing dsDNA binding.","method":"In vitro nuclease inhibition assays with purified DFF40/CAD; structural mapping to homodimer surface","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro biochemical assay with structural interpretation, single lab, single method","pmids":["16699957"],"is_preprint":false},{"year":2003,"finding":"CIIA (CAD inhibitor that interacts with ASK1) binds directly to CAD and inhibits its nuclease activity without affecting caspase-3-mediated ICAD cleavage; CIIA also inhibits ASK1 oligomerization-dependent activation; antisense knockdown of endogenous CIIA promotes DNA fragmentation and apoptosis.","method":"Co-immunoprecipitation; in vitro nuclease activity assay; antisense knockdown in L929 cells; apoptosis assays","journal":"The Journal of Cell Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional nuclease assay plus knockdown, single lab","pmids":["14557248"],"is_preprint":false},{"year":1986,"finding":"The dihydroorotase (DHO) domain of CAD is located at the extreme amino terminus of the polypeptide; it contains one tightly bound zinc atom per subunit that participates in catalysis; the isolated 44 kDa domain forms a concentration-dependent dimer–monomer equilibrium; chelating agents inhibit its activity.","method":"Controlled elastase proteolysis of CAD; atomic absorption spectrophotometry; 65Zn radiolabeling; hydrodynamic characterization; chelator inhibition assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical isolation, radioisotope confirmation of zinc content, multiple orthogonal methods","pmids":["2871022"],"is_preprint":false},{"year":1983,"finding":"The aspartate transcarbamylase (ATCase) domain of CAD is a distinct ~40 kDa structural domain released by early controlled proteolysis; it forms an oligomer of 2–3 subunits; its kinetic parameters (Km, Vmax) closely match those of intact CAD, but the isolated domain is less stable (half-life 10.6 h vs 60.2 h for intact CAD), indicating stabilizing interactions with adjacent domains.","method":"Controlled proteolysis; ion-exchange chromatography purification; SDS-PAGE; steady-state kinetics; thermal stability assay","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain isolation with rigorous kinetic and structural characterization, multiple orthogonal methods","pmids":["6300078"],"is_preprint":false},{"year":1988,"finding":"Domain order in CAD is GLNase-CPSase-DHOase-ATCase (confirmed by antibody probing of limited proteolysis fragments, ruling out the previously proposed DHOase-GLNase-CPSase-ATCase order). Phosphorylation by cAMP-dependent protein kinase (PKA) at two sites (site 1 near C-terminal end of CPSase domain, site 2 unmapped) accelerates protease cleavage of CAD and abolishes the protective effect of UTP.","method":"Limited proteolysis with elastase/trypsin; immunoblotting with domain-specific antibodies; in vitro PKA phosphorylation; analytical isoelectric focusing of tryptic phosphopeptides","journal":"European Journal of Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (proteolysis mapping, domain antibodies, phosphopeptide analysis), rules out alternative model","pmids":["3345746"],"is_preprint":false},{"year":1988,"finding":"CAD is predominantly cytosolic in mammalian cells with a punctate distribution suggesting association with subcellular structures, not uniformly soluble; it is largely excluded from the nucleus and not concentrated near mitochondria, indicating that the intermediate dihydroorotate diffuses freely rather than being channeled to the mitochondrial enzyme dihydroorotate dehydrogenase.","method":"Differential centrifugation fractionation; immunocytochemical localization (two methods); immunofluorescence microscopy in BHK cells","journal":"FASEB Journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent localization methods plus fractionation, single lab","pmids":["2903106"],"is_preprint":false},{"year":2005,"finding":"MAP kinase (ERK1/2) phosphorylates CAD at Thr-456 to activate de novo pyrimidine biosynthesis; phospho-Thr-456 CAD is preferentially localized in the nucleus associated with insoluble nuclear substructures including the nuclear matrix. Nuclear import of CAD is not driven by MAP kinase phosphorylation itself. When CAD is excluded from the nucleus (NES-CAD construct), pyrimidine biosynthesis rate, nucleotide pools, and cell growth are each reduced (~21%, 36%, and 60% respectively), demonstrating that nuclear localization is required for optimal pathway activity.","method":"Cell fractionation; fluorescence microscopy; phospho-specific antibodies; Thr-456 mutagenesis; NLS-CAD and NES-CAD fluorescent constructs; HPLC nucleotide pool measurement; growth rate assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (fractionation, imaging, mutagenesis, metabolic assays), functional consequence of localization demonstrated","pmids":["15890648"],"is_preprint":false},{"year":2007,"finding":"CAD Thr-456 phosphorylation by MAP kinase (ERK1/2) activates pyrimidine biosynthesis; PKA phosphorylation of Ser-1406 antagonizes this by blocking ERK-mediated Thr-456 phosphorylation (and vice versa). Both MAP kinase and PKA form stable complexes with CAD, and the mutual antagonism results from steric interference by bound kinases. PKC (delta and epsilon isoforms) phosphorylates CAD at Ser-1873 and promotes MAP kinase phosphorylation of Thr-456 in a PKC-dependent manner; deletion of Ser-1873 abolishes PMA-induced Thr-456 phosphorylation.","method":"In vitro kinase assays with purified CAD and PKC isoforms; LC/MS phosphosite identification; PKC activator (PMA) and inhibitor treatments; Co-immunoprecipitation of kinase-CAD complexes; deletion mutagenesis","journal":"Molecular and Cellular Biochemistry / Frontiers in Bioscience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assays plus mutagenesis plus in vivo pharmacological validation, multiple orthogonal approaches","pmids":["17206380","17485345"],"is_preprint":false},{"year":2022,"finding":"Oncogenic β-catenin transcriptionally upregulates AKT2, which then phosphorylates CAD at Ser-1406 and Ser-1859 to potentiate de novo pyrimidine synthesis, driving hepatocellular carcinoma proliferation. Inhibition of the β-catenin/AKT2/CAD axis preferentially suppressed β-catenin mutant cell proliferation and tumor formation.","method":"Untargeted metabolomics; reporter gene assays; phospho-site identification by mass spectrometry; siRNA knockdown; mouse liver tumor models; pharmacological inhibition","journal":"Proceedings of the National Academy of Sciences USA","confidence":"High","confidence_rationale":"Tier 2 / Moderate — metabolomics plus mechanistic phosphorylation mapping plus in vivo mouse models, single lab with multiple orthogonal methods","pmids":["36122209"],"is_preprint":false},{"year":2023,"finding":"CAD de novo pyrimidine synthesis is allosterically regulated during the cell cycle by UTP binding to two Animalia-specific loops in the CAD allosteric domain; these loops sense and bind UTP (a CAD allosteric inhibitor), and a signal transmission loop controls formation of the substrate channel to regulate CAD activity. Mutation scanning established that allostery is the primary mechanism of cell-cycle-phase-dependent CAD activity change.","method":"Cell synchronization + metabolomics; systematic mutational scanning; structural modeling based on mitochondrial CPS homologue; in cellulo CAD activity assays","journal":"Nature Metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutational scanning combined with structural modelling and metabolomics in synchronized cells, single lab with multiple orthogonal methods","pmids":["36747088"],"is_preprint":false},{"year":1998,"finding":"Adenovirus precursor terminal protein (pTP) physically binds to CAD at active viral DNA replication sites on the nuclear matrix; pTP-CAD complexes are immunoprecipitable from cell extracts and from in vitro-translated proteins; both pTP and CAD co-localize in nuclear foci that also contain sites of active DNA replication (BrdU incorporation).","method":"Far-Western blotting; amino acid sequencing; co-immunoprecipitation from cell extracts; in vitro translation co-IP; confocal co-localization immunofluorescence","journal":"Journal of Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and in vitro binding plus co-localization, single lab","pmids":["9525610"],"is_preprint":false},{"year":2020,"finding":"Ebola virus nucleoprotein NP directly interacts with CAD and recruits it into viral inclusion bodies; this recruitment depends on the glutaminase (GLN) domain of CAD. siRNA knockdown of CAD impairs both EBOV genome replication and transcription; substrate rescue experiments demonstrate that CAD's pyrimidine synthesis function is required for these processes.","method":"Co-immunoprecipitation; co-immunofluorescence; siRNA knockdown; reverse genetics life-cycle modelling; substrate (uridine) rescue experiments; GLN-domain deletion constructs","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus domain mapping plus functional knockdown with rescue, single lab","pmids":["32370067"],"is_preprint":false},{"year":2012,"finding":"CAD (the pyrimidine biosynthesis enzyme) binds directly to NOD2 and inhibits NOD2-dependent NF-κB and p38 MAPK activation as well as intracellular killing of Salmonella; reduction of CAD expression or pharmacological CAD inhibition enhances NOD2 antibacterial signaling function, identifying CAD as a negative regulator of NOD2.","method":"Immunoprecipitation-coupled mass spectrometry identification of NOD2 interactome; co-immunoprecipitation; reporter gene assays; gentamicin protection assay; siRNA knockdown; CAD inhibitor treatment","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification confirmed by Co-IP and functional knockdown/inhibitor assays, single lab","pmids":["22387394"],"is_preprint":false},{"year":2011,"finding":"CAD (pyrimidine biosynthesis enzyme) physically interacts with the androgen receptor (AR) in prostate tumor cells and promotes AR nuclear translocation and transcriptional activity, revealing a non-metabolic function of CAD in nuclear receptor signaling.","method":"AR immunopurification from xenograft tumors; co-immunoprecipitation in prostate cell lines; AR transcriptional reporter assays; nuclear localization imaging","journal":"FASEB Journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional transcriptional assay plus localization, single lab","pmids":["21982950"],"is_preprint":false},{"year":2017,"finding":"Executioner caspase activation of CAD/DFF40 endonuclease is essential for TRAIL-induced mutagenesis and for vincristine-induced mutagenesis in surviving cells; this identifies a non-apoptotic, pro-mutagenic role for caspase-activated CAD.","method":"Genetic knockout/inhibition of executioner caspases and CAD; mutation frequency assays in surviving cells after TRAIL or vincristine treatment","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic loss-of-function with specific mutagenesis phenotype readout, single lab","pmids":["28981092"],"is_preprint":false},{"year":2022,"finding":"CAD activity persists in memory CD8+ T cells after initial activation (sustained phosphorylation in mTORC1-dependent manner) and supports ongoing de novo pyrimidine synthesis required for pre-rRNA synthesis and ribosomal biogenesis; CAD inhibition reduces ribosomal protein levels and diminishes the speed and magnitude of cytokine production upon rechallenge, while CAD overexpression enhances recall responses.","method":"CAD activity/phosphorylation assays in resting vs. activated T cells; metabolomics; CAD inhibitor treatment; CAD overexpression; pre-rRNA and ribosomal protein quantification; cytokine production assays","journal":"Science Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus overexpression with multiple functional readouts, single lab","pmids":["35622902"],"is_preprint":false},{"year":2023,"finding":"Crystal structures of the dihydroorotase domain of human CAD (huDHOase) complexed with 5-fluorouracil (1.97 Å) and with malate reveal that, unlike the E. coli DHOase, huDHOase binds non-substrate ligands in a loop-in mode at the active site; site-directed mutagenesis and fluorescence quenching confirmed the binding interaction, identifying the dynamic active-site loop as a drug-targeting site.","method":"X-ray crystallography (1.97 Å); site-directed mutagenesis; fluorescence quenching binding assay","journal":"Biomolecules","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure determination plus mutagenesis plus independent binding assay, single lab","pmids":["36671534"],"is_preprint":false},{"year":2021,"finding":"Afatinib (EGFR-TKI) directly targets CAD, the key de novo pyrimidine biosynthesis enzyme, suppressing CD8+ T lymphocyte proliferation; this mechanism underlies afatinib-mediated immunosuppression distinct from its EGFR kinase inhibition.","method":"Biochemical target identification of afatinib binding to CAD; CD8+ T cell proliferation assays with afatinib; in vivo Lewis lung carcinoma and MC38 tumor models; tumor-infiltrating lymphocyte quantification","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical target identification plus functional in vitro and in vivo validation, single lab","pmids":["33771897"],"is_preprint":false},{"year":2013,"finding":"The ATCase domain of human CAD forms homotrimers in solution and crystallizes in space group P6322 (2.1 Å resolution), establishing the structural basis for CAD hexamer formation through ATCase trimer-of-trimers interactions.","method":"Recombinant domain expression in bacteria; gel filtration (homotrimer confirmation); X-ray crystallography (2.1 Å)","journal":"Acta Crystallographica Section F","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystallographic structure of isolated domain, preliminary diffraction data reported, single lab","pmids":["24316846"],"is_preprint":false},{"year":2020,"finding":"CRISPR/Cas9 knockout of CAD in human cells confirmed that CAD enzymatic activity is required for cell survival in the absence of exogenous uridine; a complementation assay using transient transfection of recombinant CAD into knockout cells was validated as a reliable pathogenicity test for CAD missense variants.","method":"CRISPR/Cas9 gene knockout; uridine-dependent growth complementation assay; transient transfection of variant CAD constructs","journal":"Genetics in Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined metabolic phenotype, complementation assay validated across 34 variants in multiple labs/patients","pmids":["32461667"],"is_preprint":false}],"current_model":"CAD is a ~250 kDa multienzymatic protein (organized GLNase-CPSase-DHOase-ATCase from N to C terminus) that hexamerizes to form a ~1.5 MDa particle catalyzing the first three rate-limiting steps of de novo pyrimidine biosynthesis; its activity is cell-cycle regulated by sequential phosphorylation—MAP kinase (ERK1/2) activates it at Thr-456 after nuclear import, PKA antagonizes this at Ser-1406/Ser-1859, and PKC delta/epsilon modulate ERK access via Ser-1873—while UTP allosterically inhibits it through Animalia-specific loops controlling a substrate channel; in apoptosis a completely separate ~40 kDa nuclease function (CAD/DFF40) is activated when caspase-3 cleaves its inhibitor ICAD, releasing active CAD homodimers that specifically cleave internucleosomal double-stranded DNA in a Mg2+-dependent manner to produce oligonucleosomal laddering and drive final chromatin condensation; beyond these canonical roles, CAD interacts with the androgen receptor to promote its nuclear translocation, with NOD2 to suppress antibacterial signaling, with Ebola NP to supply pyrimidines for viral replication, and is a direct target of the EGFR inhibitor afatinib, thereby suppressing T cell proliferation."},"narrative":{"mechanistic_narrative":"CAD is a multienzymatic protein that catalyzes the first three rate-limiting steps of de novo pyrimidine biosynthesis through an N-to-C domain arrangement of GLNase-CPSase-DHOase-ATCase [PMID:3345746], with the N-terminal dihydroorotase domain carrying a single catalytic zinc atom [PMID:2871022] and the C-terminal ATCase domain forming homotrimers that provide the trimer-of-trimers interface underlying CAD oligomerization [PMID:24316846]. Pathway flux is governed by sequential phosphorylation: ERK1/2 (MAP kinase) activates CAD at Thr-456 [PMID:15890648, PMID:17206380, PMID:17485345], an event antagonized by PKA phosphorylation at Ser-1406 through steric interference between stably bound kinases, while PKC delta/epsilon phosphorylation at Ser-1873 promotes ERK access [PMID:17206380, PMID:17485345]; in tumors, oncogenic beta-catenin drives an AKT2-dependent CAD phosphorylation at Ser-1406/Ser-1859 to potentiate proliferation [PMID:36122209]. Activation requires CAD to be imported into the nucleus, where phospho-Thr-456 CAD associates with the nuclear matrix and nuclear localization is needed for optimal pyrimidine synthesis, nucleotide pools, and growth [PMID:15890648], and across the cell cycle activity is set allosterically by UTP binding to two Animalia-specific loops that gate the substrate channel [PMID:36747088]. CAD enzymatic activity is essential for cell survival without exogenous uridine, and its complementation assay defines pathogenicity of disease-associated CAD missense variants [PMID:32461667]. Entirely separately, CAD also denotes the apoptotic endonuclease CAD/DFF40, held inactive by its inhibitor ICAD/DFF45 until caspase-3 cleaves ICAD to release CAD homodimers [PMID:9422513, PMID:15149602] that, as a Mg2+-dependent enzyme acting specifically on double-stranded DNA, cleave internucleosomal linker DNA to drive oligonucleosomal laddering and final chromatin condensation [PMID:11577114, PMID:11330826]. Beyond these roles, CAD physically engages partners that co-opt its pyrimidine output or non-metabolic activity, including the androgen receptor to promote its nuclear translocation [PMID:21982950], NOD2 to suppress antibacterial NF-kappaB/p38 signaling [PMID:22387394], and Ebola virus NP, which recruits CAD via its glutaminase domain to supply pyrimidines for viral replication [PMID:32370067].","teleology":[{"year":1983,"claim":"Establishing that CAD's catalytic activities reside in separable, autonomously folding domains was the first step in defining how one polypeptide performs multiple enzymatic steps.","evidence":"Controlled proteolysis and kinetic/thermal characterization of the released ~40 kDa ATCase domain","pmids":["6300078"],"confidence":"High","gaps":["Did not establish full domain order","Stabilizing inter-domain contacts inferred from stability differences, not structurally resolved"]},{"year":1986,"claim":"Localizing the dihydroorotase domain to the extreme N-terminus and identifying its catalytic zinc clarified the chemistry of one CAD active site.","evidence":"Elastase proteolysis, 65Zn radiolabeling, atomic absorption, and chelator inhibition of the isolated 44 kDa domain","pmids":["2871022"],"confidence":"High","gaps":["Catalytic mechanism of zinc not resolved at atomic level here","Did not address regulation of the domain in intact CAD"]},{"year":1988,"claim":"Resolving the definitive GLNase-CPSase-DHOase-ATCase domain order and demonstrating PKA phosphorylation that abolishes UTP protection linked CAD architecture to its regulation.","evidence":"Limited proteolysis with domain-specific antibodies plus in vitro PKA phosphorylation and phosphopeptide mapping","pmids":["3345746"],"confidence":"High","gaps":["Second PKA phosphosite unmapped","Physiological consequence of PKA phosphorylation on flux not measured"]},{"year":1988,"claim":"Subcellular localization addressed whether CAD channels its intermediate to mitochondria, showing it is cytosolic and punctate rather than mitochondria-associated.","evidence":"Differential centrifugation and dual immunocytochemical localization in BHK cells","pmids":["2903106"],"confidence":"Medium","gaps":["Did not resolve the nature of the punctate structures","Predates discovery of activation-dependent nuclear import"]},{"year":1998,"claim":"Identifying caspase-3 cleavage of ICAD as the trigger that releases CAD/DFF40 explained how apoptotic DNA fragmentation is switched on.","evidence":"Site-directed mutagenesis of ICAD cleavage sites and rescue in Fas/staurosporine-treated Jurkat cells","pmids":["9422513"],"confidence":"High","gaps":["Did not resolve the structural basis of CAD activation","Did not distinguish CAD's contribution from other apoptotic nucleases"]},{"year":1998,"claim":"Demonstrating that CAD binds adenovirus pTP at nuclear-matrix replication sites was the first link between CAD and viral DNA replication machinery.","evidence":"Far-Western, reciprocal Co-IP, and confocal co-localization with BrdU incorporation sites","pmids":["9525610"],"confidence":"Medium","gaps":["Functional requirement of CAD for viral replication not tested","Which CAD function (metabolic vs structural) is involved unresolved"]},{"year":2000,"claim":"Defining the CAD-domain ubiquitin superfold and its tight binding to ICAD established the molecular basis of nuclease inhibition and folding.","evidence":"Multidimensional NMR structure and SPR binding measurement (Kd ~55 nM)","pmids":["10764577"],"confidence":"High","gaps":["Did not capture the full active dimer","Mechanism coupling inhibition to folding inferred, not directly observed"]},{"year":2001,"claim":"Genetic knockout assigned CAD/DFF40 specifically to oligonucleosomal fragmentation and late nuclear condensation, revealing distinct earlier-acting nucleases.","evidence":"CAD-/- DT40 cells with full ORF deletion, DNA electrophoresis, and nuclear morphology across apoptotic stimuli","pmids":["11577114"],"confidence":"High","gaps":["Identity of the high-molecular-weight cleavage nucleases not established","Did not address non-apoptotic functions"]},{"year":2001,"claim":"Biochemical reconstitution defined CAD/DFF40 as a Mg2+-dependent dsDNA endonuclease tuned to apoptotic ionic conditions.","evidence":"In vitro endonuclease assays varying K+, divalent metals, and pH with purified enzyme","pmids":["11330826"],"confidence":"High","gaps":["Single lab","In vitro conditions may not fully recapitulate chromatin context"]},{"year":2003,"claim":"Identifying CIIA as a direct CAD-binding inhibitor that acts downstream of ICAD cleavage revealed an additional layer of nuclease control.","evidence":"Reciprocal Co-IP, in vitro nuclease assay, and antisense knockdown in L929 cells","pmids":["14557248"],"confidence":"Medium","gaps":["Single lab without structural mapping of the CIIA-CAD interface","Physiological dominance over ICAD regulation unclear"]},{"year":2004,"claim":"The activated CAD/DFF40 crystal structure showed it is a homodimer with a linker-DNA-cleaving crevice and clarified how ICAD assembles or disassembles it.","evidence":"X-ray crystallography of activated CAD/DFF40 with biochemical dimer assembly/disassembly assays","pmids":["15149602"],"confidence":"High","gaps":["Did not capture DNA-bound state","Catalytic mechanism at the metal site not resolved"]},{"year":2005,"claim":"Showing that ERK-mediated Thr-456 phosphorylation activates CAD and that nuclear localization is required for optimal pathway flux connected signaling, localization, and metabolic output.","evidence":"Phospho-specific antibodies, Thr-456 mutagenesis, NLS/NES-CAD constructs, HPLC nucleotide pools, and growth assays","pmids":["15890648"],"confidence":"High","gaps":["Mechanism driving CAD nuclear import not identified","Nature of nuclear-matrix association unresolved"]},{"year":2006,"claim":"Mapping polyanion inhibition to the alpha-4 helices of the DFF40 dimer explained how RNA and other polyanions block dsDNA binding.","evidence":"In vitro nuclease inhibition assays with structural surface mapping","pmids":["16699957"],"confidence":"Medium","gaps":["Single lab, single method","Physiological relevance of polyanion inhibition in vivo not tested"]},{"year":2008,"claim":"Demonstrating exclusive dsDNA cleavage with competitive inhibition by other nucleic acids refined CAD/DFF40 substrate specificity.","evidence":"In vitro nuclease assays with synthetic ribo/deoxyribo oligonucleotides plus apoptosis RNA correlation","pmids":["18283539"],"confidence":"High","gaps":["Did not structurally define the DNA-binding site","In vivo competition by cellular RNA not quantified"]},{"year":2007,"claim":"Establishing reciprocal antagonism among ERK, PKA, and PKC at distinct CAD phosphosites defined the integrated kinase code controlling pyrimidine synthesis.","evidence":"In vitro kinase assays, LC/MS phosphosite mapping, PMA/inhibitor treatments, kinase-CAD Co-IP, and deletion mutagenesis","pmids":["17206380","17485345"],"confidence":"High","gaps":["Quantitative contribution of each phosphosite to in vivo flux not fully resolved","Structural basis of steric kinase interference inferred, not visualized"]},{"year":2011,"claim":"Linking CAD to androgen receptor nuclear translocation revealed a non-metabolic function in nuclear receptor signaling.","evidence":"AR immunopurification from xenografts, Co-IP in prostate cells, AR reporter assays, and localization imaging","pmids":["21982950"],"confidence":"Medium","gaps":["Single lab without structural interaction mapping","Whether CAD enzymatic activity is required for AR effect untested"]},{"year":2012,"claim":"Identifying CAD as a direct NOD2 binder that suppresses antibacterial signaling assigned it a negative-regulatory role in innate immunity.","evidence":"IP-MS interactome, Co-IP, NF-kappaB/p38 reporters, gentamicin protection, siRNA, and CAD inhibitor treatment","pmids":["22387394"],"confidence":"Medium","gaps":["Single lab","Whether the inhibitory effect depends on CAD catalytic activity not resolved"]},{"year":2013,"claim":"Solving the human ATCase domain homotrimer structure established the structural basis for CAD hexamer assembly.","evidence":"Recombinant domain expression, gel filtration, and X-ray crystallography at 2.1 Å","pmids":["24316846"],"confidence":"Medium","gaps":["Isolated domain only; full-length hexamer not solved","Preliminary diffraction data, single lab"]},{"year":2017,"claim":"Showing that caspase-activated CAD/DFF40 drives mutagenesis in surviving cells revealed a non-apoptotic, pro-mutagenic role.","evidence":"Genetic loss-of-function of executioner caspases and CAD with mutation-frequency assays after TRAIL or vincristine","pmids":["28981092"],"confidence":"Medium","gaps":["Single lab","Mechanism by which sublethal CAD activity produces mutations not detailed"]},{"year":2020,"claim":"Ebola NP was shown to recruit CAD via its glutaminase domain to supply pyrimidines required for viral replication and transcription.","evidence":"Co-IP, co-immunofluorescence, siRNA knockdown, reverse genetics, GLN-domain deletion, and uridine rescue","pmids":["32370067"],"confidence":"Medium","gaps":["Single lab","Structural basis of NP-GLN domain binding unresolved"]},{"year":2020,"claim":"CRISPR knockout established CAD enzymatic activity as essential without exogenous uridine and validated a complementation assay for variant pathogenicity, linking CAD to human disease genetics.","evidence":"CRISPR/Cas9 knockout, uridine-dependent growth complementation, and transient transfection of variant constructs across 34 variants","pmids":["32461667"],"confidence":"High","gaps":["Did not enumerate the clinical disease phenotype mechanistically","Variant effects on specific catalytic steps not dissected"]},{"year":2021,"claim":"Identifying CAD as a direct afatinib target explained an EGFR-kinase-independent immunosuppressive effect on CD8+ T cells.","evidence":"Biochemical target identification, T cell proliferation assays, and in vivo LLC/MC38 tumor models with TIL quantification","pmids":["33771897"],"confidence":"Medium","gaps":["Single lab","Afatinib binding site on CAD not structurally defined"]},{"year":2022,"claim":"Defining a beta-catenin/AKT2/CAD phosphorylation axis at Ser-1406/Ser-1859 linked oncogenic signaling to pyrimidine-driven hepatocellular carcinoma growth.","evidence":"Untargeted metabolomics, reporter assays, MS phosphosite mapping, siRNA, mouse liver tumor models, and pharmacological inhibition","pmids":["36122209"],"confidence":"High","gaps":["Interplay with ERK/PKA phosphorylation not resolved","Whether AKT2 acts on the same residues across tissues untested"]},{"year":2022,"claim":"Demonstrating sustained mTORC1-dependent CAD activity in memory CD8+ T cells coupled pyrimidine synthesis to ribosome biogenesis and recall responses.","evidence":"CAD phosphorylation/activity assays, metabolomics, inhibition, overexpression, pre-rRNA and ribosomal protein quantification, and cytokine assays","pmids":["35622902"],"confidence":"Medium","gaps":["Single lab","Direct connection between pyrimidine pools and rRNA synthesis mechanistically partial"]},{"year":2023,"claim":"Identifying UTP-sensing Animalia-specific allosteric loops controlling the substrate channel established allostery as the primary driver of cell-cycle-dependent CAD activity.","evidence":"Cell synchronization with metabolomics, systematic mutational scanning, structural modeling, and in cellulo activity assays","pmids":["36747088"],"confidence":"High","gaps":["Allosteric mechanism modeled rather than crystallographically resolved in full-length CAD","Interplay between allostery and phosphorylation not integrated"]},{"year":2023,"claim":"Crystal structures of the human DHOase domain with non-substrate ligands revealed a loop-in binding mode distinct from E. coli, identifying a druggable active-site loop.","evidence":"X-ray crystallography at 1.97 Å with 5-fluorouracil and malate, mutagenesis, and fluorescence quenching","pmids":["36671534"],"confidence":"High","gaps":["Drug efficacy of loop targeting not demonstrated in cells","Single lab"]},{"year":null,"claim":"How the metabolic kinase/allosteric regulatory network, the nuclear-import requirement, and the diverse partner-driven moonlighting functions are integrated within the assembled CAD hexamer in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No full-length hexamer structure linking domains and regulatory sites","Mechanism of activation-dependent nuclear import unidentified","Whether moonlighting interactions require catalytic activity largely untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[10]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[8,22]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[9,24]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[3,4,5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[10,25]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[12,15]}],"complexes":["CAD hexamer","CAD/DFF40-ICAD/DFF45 complex"],"partners":["ICAD","CIIA","NOD2","AR","AKT2","EBOLA NP","ADENOVIRUS PTP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O76075","full_name":"DNA fragmentation factor subunit beta","aliases":["Caspase-activated deoxyribonuclease","CAD","Caspase-activated DNase","Caspase-activated nuclease","CPAN","DNA fragmentation factor 40 kDa subunit","DFF-40"],"length_aa":338,"mass_kda":39.1,"function":"Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/O76075/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CAD","classification":"Not Classified","n_dependent_lines":485,"n_total_lines":1208,"dependency_fraction":0.4014900662251656},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000084774","cell_line_id":"CID000996","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"MRTO4","stoichiometry":10.0},{"gene":"CDC37","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"MIF","stoichiometry":0.2},{"gene":"PTGES3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000996","total_profiled":1310},"omim":[{"mim_id":"620291","title":"WD REPEAT-CONTAINING PROTEIN 18; WDR18","url":"https://www.omim.org/entry/620291"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"},{"mim_id":"619858","title":"AUTOINFLAMMATORY-PANCYTOPENIA SYNDROME; AIPCS","url":"https://www.omim.org/entry/619858"},{"mim_id":"619836","title":"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 2, INTERMEDIATE","url":"https://www.omim.org/entry/619836"},{"mim_id":"618979","title":"HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 7; HDLCQ7","url":"https://www.omim.org/entry/618979"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CAD"},"hgnc":{"alias_symbol":["GATD4"],"prev_symbol":[]},"alphafold":{"accession":"O76075","domains":[{"cath_id":"3.10.20.10","chopping":"7-84","consensus_level":"high","plddt":93.8833,"start":7,"end":84},{"cath_id":"-","chopping":"153-307","consensus_level":"high","plddt":95.2195,"start":153,"end":307},{"cath_id":"1.10.287","chopping":"96-128","consensus_level":"high","plddt":91.8948,"start":96,"end":128}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76075","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76075-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76075-F1-predicted_aligned_error_v6.png","plddt_mean":92.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CAD","jax_strain_url":"https://www.jax.org/strain/search?query=CAD"},"sequence":{"accession":"O76075","fasta_url":"https://rest.uniprot.org/uniprotkb/O76075.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76075/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76075"}},"corpus_meta":[{"pmid":"9422513","id":"PMC_9422513","title":"Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9422513","citation_count":1355,"is_preprint":false},{"pmid":"15723341","id":"PMC_15723341","title":"Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15723341","citation_count":166,"is_preprint":false},{"pmid":"28007989","id":"PMC_28007989","title":"CAD mutations and uridine-responsive epileptic encephalopathy.","date":"2016","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28007989","citation_count":94,"is_preprint":false},{"pmid":"15149602","id":"PMC_15149602","title":"Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15149602","citation_count":90,"is_preprint":false},{"pmid":"11577114","id":"PMC_11577114","title":"CAD/DFF40 nuclease is dispensable for high molecular weight DNA cleavage and stage I chromatin condensation in apoptosis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11577114","citation_count":87,"is_preprint":false},{"pmid":"18584171","id":"PMC_18584171","title":"Cloning and functional characterization of the cis-aconitic acid decarboxylase (CAD) gene from Aspergillus terreus.","date":"2008","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18584171","citation_count":84,"is_preprint":false},{"pmid":"11996094","id":"PMC_11996094","title":"The DFF40/CAD endonuclease and its role in apoptosis.","date":"2000","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/11996094","citation_count":82,"is_preprint":false},{"pmid":"23667179","id":"PMC_23667179","title":"Identification of CAD candidate genes in GWAS loci and their expression in vascular cells.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23667179","citation_count":82,"is_preprint":false},{"pmid":"18007590","id":"PMC_18007590","title":"The CENP-A NAC/CAD kinetochore complex controls chromosome congression and spindle bipolarity.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18007590","citation_count":77,"is_preprint":false},{"pmid":"2871022","id":"PMC_2871022","title":"The dihydroorotase domain of the multifunctional protein CAD. Subunit structure, zinc content, and kinetics.","date":"1986","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2871022","citation_count":72,"is_preprint":false},{"pmid":"3023056","id":"PMC_3023056","title":"Structure of DNA formed in the first step of CAD gene amplification.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3023056","citation_count":72,"is_preprint":false},{"pmid":"6277500","id":"PMC_6277500","title":"The cloning and reintroduction into animal cells of a functional CAD gene, a dominant amplifiable genetic marker.","date":"1981","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/6277500","citation_count":69,"is_preprint":false},{"pmid":"6125880","id":"PMC_6125880","title":"Structure of the gene for CAD, the multifunctional protein that initiates UMP synthesis in Syrian hamster cells.","date":"1982","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/6125880","citation_count":68,"is_preprint":false},{"pmid":"34638594","id":"PMC_34638594","title":"Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34638594","citation_count":67,"is_preprint":false},{"pmid":"26633560","id":"PMC_26633560","title":"Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26633560","citation_count":64,"is_preprint":false},{"pmid":"3990684","id":"PMC_3990684","title":"Abundant nuclear ribonucleoprotein form of CAD RNA.","date":"1985","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3990684","citation_count":55,"is_preprint":false},{"pmid":"24112972","id":"PMC_24112972","title":"The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24112972","citation_count":50,"is_preprint":false},{"pmid":"11752060","id":"PMC_11752060","title":"Implications of CAD and DNase II in ischemic neuronal necrosis specific for the primate hippocampus.","date":"2001","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11752060","citation_count":50,"is_preprint":false},{"pmid":"6300078","id":"PMC_6300078","title":"The isolation and characterization of the aspartate transcarbamylase domain of the multifunctional protein, CAD.","date":"1983","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6300078","citation_count":50,"is_preprint":false},{"pmid":"2569669","id":"PMC_2569669","title":"Evolution and stability of chromosomal DNA coamplified with the CAD gene.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2569669","citation_count":48,"is_preprint":false},{"pmid":"11330826","id":"PMC_11330826","title":"Ionic and cofactor requirements for the activity of the apoptotic endonuclease DFF40/CAD.","date":"2001","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11330826","citation_count":42,"is_preprint":false},{"pmid":"31939163","id":"PMC_31939163","title":"CAD, A Multienzymatic Protein at the Head of de Novo Pyrimidine Biosynthesis.","date":"2019","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31939163","citation_count":41,"is_preprint":false},{"pmid":"29937172","id":"PMC_29937172","title":"Low-cost, self-made CAD/CAM-guiding system for mandibular reconstruction.","date":"2018","source":"Surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29937172","citation_count":41,"is_preprint":false},{"pmid":"11717437","id":"PMC_11717437","title":"High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11717437","citation_count":40,"is_preprint":false},{"pmid":"31484458","id":"PMC_31484458","title":"Biocompatibility of Polymer and Ceramic CAD/CAM Materials with Human Gingival Fibroblasts (HGFs).","date":"2019","source":"Polymers","url":"https://pubmed.ncbi.nlm.nih.gov/31484458","citation_count":40,"is_preprint":false},{"pmid":"7623808","id":"PMC_7623808","title":"Identification of an origin of bidirectional DNA replication in the ubiquitously expressed mammalian CAD gene.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7623808","citation_count":40,"is_preprint":false},{"pmid":"14557248","id":"PMC_14557248","title":"Identification of a novel antiapoptotic protein that antagonizes ASK1 and CAD activities.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14557248","citation_count":39,"is_preprint":false},{"pmid":"20577898","id":"PMC_20577898","title":"Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.","date":"2010","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20577898","citation_count":39,"is_preprint":false},{"pmid":"3345746","id":"PMC_3345746","title":"Mapping of catalytic domains and phosphorylation sites in the multifunctional pyrimidine-biosynthetic protein CAD.","date":"1988","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3345746","citation_count":38,"is_preprint":false},{"pmid":"9525610","id":"PMC_9525610","title":"Adenovirus preterminal protein binds to the CAD enzyme at active sites of viral DNA replication on the nuclear matrix.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9525610","citation_count":37,"is_preprint":false},{"pmid":"34288185","id":"PMC_34288185","title":"Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease.","date":"2021","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/34288185","citation_count":36,"is_preprint":false},{"pmid":"36122209","id":"PMC_36122209","title":"Oncogenic β-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36122209","citation_count":35,"is_preprint":false},{"pmid":"15890648","id":"PMC_15890648","title":"Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15890648","citation_count":34,"is_preprint":false},{"pmid":"28981092","id":"PMC_28981092","title":"Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28981092","citation_count":33,"is_preprint":false},{"pmid":"10764577","id":"PMC_10764577","title":"Structure of the CAD domain of caspase-activated DNase and interaction with the CAD domain of its inhibitor.","date":"2000","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10764577","citation_count":31,"is_preprint":false},{"pmid":"33771897","id":"PMC_33771897","title":"Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33771897","citation_count":30,"is_preprint":false},{"pmid":"33257084","id":"PMC_33257084","title":"Bio-mechanical characterization of a CAD/CAM PMMA resin for digital removable prostheses.","date":"2020","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/33257084","citation_count":30,"is_preprint":false},{"pmid":"36747088","id":"PMC_36747088","title":"Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36747088","citation_count":29,"is_preprint":false},{"pmid":"22387394","id":"PMC_22387394","title":"The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells.","date":"2012","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22387394","citation_count":28,"is_preprint":false},{"pmid":"29430727","id":"PMC_29430727","title":"The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT-II, in xenotransplantation.","date":"2018","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/29430727","citation_count":27,"is_preprint":false},{"pmid":"33179842","id":"PMC_33179842","title":"CBS and MAT2A improve methionine-mediated DNA synthesis through SAMTOR/mTORC1/S6K1/CAD pathway during embryo implantation.","date":"2020","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/33179842","citation_count":27,"is_preprint":false},{"pmid":"10467348","id":"PMC_10467348","title":"Structure and promoter analysis of murine CAD and ICAD genes.","date":"1999","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10467348","citation_count":27,"is_preprint":false},{"pmid":"35626694","id":"PMC_35626694","title":"Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35626694","citation_count":27,"is_preprint":false},{"pmid":"37631336","id":"PMC_37631336","title":"The Effects of Thermocycling on the Physical Properties and Biocompatibilities of Various CAD/CAM Restorative Materials.","date":"2023","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/37631336","citation_count":27,"is_preprint":false},{"pmid":"34484864","id":"PMC_34484864","title":"CAD increases the long noncoding RNA PUNISHER in small extracellular vesicles and regulates endothelial cell function via vesicular shuttling.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/34484864","citation_count":27,"is_preprint":false},{"pmid":"32820246","id":"PMC_32820246","title":"Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation.","date":"2020","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32820246","citation_count":27,"is_preprint":false},{"pmid":"22212487","id":"PMC_22212487","title":"PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.","date":"2012","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22212487","citation_count":26,"is_preprint":false},{"pmid":"36453704","id":"PMC_36453704","title":"Circ-E-Cad encodes a protein that promotes the proliferation and migration of gastric cancer via the TGF-β/Smad/C-E-Cad/PI3K/AKT pathway.","date":"2022","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36453704","citation_count":25,"is_preprint":false},{"pmid":"34575861","id":"PMC_34575861","title":"The Connection between Czc and Cad Systems Involved in Cadmium Resistance in Pseudomonas putida.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34575861","citation_count":25,"is_preprint":false},{"pmid":"32370067","id":"PMC_32370067","title":"The Cellular Protein CAD is Recruited into Ebola Virus Inclusion Bodies by the Nucleoprotein NP to Facilitate Genome Replication and Transcription.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32370067","citation_count":25,"is_preprint":false},{"pmid":"32461667","id":"PMC_32461667","title":"Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy.","date":"2020","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32461667","citation_count":24,"is_preprint":false},{"pmid":"24552628","id":"PMC_24552628","title":"Manipulating cinnamyl alcohol dehydrogenase (CAD) expression in flax affects fibre composition and properties.","date":"2014","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/24552628","citation_count":24,"is_preprint":false},{"pmid":"17335077","id":"PMC_17335077","title":"Studies of the central nervous system-derived CAD cell line, a suitable model for intraneuronal transport studies?","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17335077","citation_count":24,"is_preprint":false},{"pmid":"25470794","id":"PMC_25470794","title":"Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).","date":"2015","source":"Diabetes/metabolism research and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25470794","citation_count":24,"is_preprint":false},{"pmid":"18572426","id":"PMC_18572426","title":"The cad locus of Enterobacteriaceae: more than just lysine decarboxylation.","date":"2008","source":"Anaerobe","url":"https://pubmed.ncbi.nlm.nih.gov/18572426","citation_count":23,"is_preprint":false},{"pmid":"3600632","id":"PMC_3600632","title":"Unstable and stable CAD gene amplification: importance of flanking sequences and nuclear environment in gene amplification.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3600632","citation_count":22,"is_preprint":false},{"pmid":"31056337","id":"PMC_31056337","title":"A missense mutation (p.Tyr452Cys) in the CAD gene compromises reproductive success in French Normande cattle.","date":"2019","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/31056337","citation_count":22,"is_preprint":false},{"pmid":"33590380","id":"PMC_33590380","title":"Vitamin D Receptor (VDR) Gene Polymorphisms and Risk of Coronary Artery Disease (CAD): Systematic Review and Meta-analysis.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33590380","citation_count":20,"is_preprint":false},{"pmid":"14728017","id":"PMC_14728017","title":"Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD.","date":"2001","source":"American journal of cardiovascular drugs : drugs, devices, and other interventions","url":"https://pubmed.ncbi.nlm.nih.gov/14728017","citation_count":20,"is_preprint":false},{"pmid":"32429880","id":"PMC_32429880","title":"The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis.","date":"2020","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32429880","citation_count":20,"is_preprint":false},{"pmid":"32682401","id":"PMC_32682401","title":"Association of ESR1 (rs2234693 and rs9340799), CETP (rs708272), MTHFR (rs1801133 and rs2274976) and MS (rs185087) polymorphisms with Coronary Artery Disease (CAD).","date":"2020","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32682401","citation_count":20,"is_preprint":false},{"pmid":"2903106","id":"PMC_2903106","title":"Intracellular location of the multidomain protein CAD in mammalian cells.","date":"1988","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/2903106","citation_count":20,"is_preprint":false},{"pmid":"26755073","id":"PMC_26755073","title":"An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells.","date":"2016","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26755073","citation_count":20,"is_preprint":false},{"pmid":"23242654","id":"PMC_23242654","title":"IL-6 gene polymorphisms and CAD risk: a meta-analysis.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23242654","citation_count":19,"is_preprint":false},{"pmid":"33920889","id":"PMC_33920889","title":"The Art of Designing DNA Nanostructures with CAD Software.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33920889","citation_count":19,"is_preprint":false},{"pmid":"32561116","id":"PMC_32561116","title":"Response of two gingival cell lines to CAD/CAM composite blocks.","date":"2020","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/32561116","citation_count":19,"is_preprint":false},{"pmid":"18283539","id":"PMC_18283539","title":"The major apoptotic endonuclease DFF40/CAD is a deoxyribose-specific and double-strand-specific enzyme.","date":"2008","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/18283539","citation_count":18,"is_preprint":false},{"pmid":"21982950","id":"PMC_21982950","title":"Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21982950","citation_count":18,"is_preprint":false},{"pmid":"17485345","id":"PMC_17485345","title":"Protein kinase C modulates the up-regulation of the pyrimidine biosynthetic complex, CAD, by MAP kinase.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485345","citation_count":18,"is_preprint":false},{"pmid":"34866163","id":"PMC_34866163","title":"Clinical effects with customized brackets and CAD/CAM technology: a prospective controlled study.","date":"2021","source":"Progress in orthodontics","url":"https://pubmed.ncbi.nlm.nih.gov/34866163","citation_count":17,"is_preprint":false},{"pmid":"34394332","id":"PMC_34394332","title":"Computational Analysis of Gly482Ser Single-Nucleotide Polymorphism in PPARGC1A Gene Associated with CAD, NAFLD, T2DM, Obesity, Hypertension, and Metabolic Diseases.","date":"2021","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/34394332","citation_count":17,"is_preprint":false},{"pmid":"31543237","id":"PMC_31543237","title":"Prediction and management of CAD risk based on genetic stratification.","date":"2019","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31543237","citation_count":16,"is_preprint":false},{"pmid":"37540500","id":"PMC_37540500","title":"Beyond genetics: Deciphering the impact of missense variants in CAD deficiency.","date":"2023","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/37540500","citation_count":16,"is_preprint":false},{"pmid":"21145398","id":"PMC_21145398","title":"Methadone induces CAD degradation and AIF-mediated necrotic-like cell death in neuroblastoma cells.","date":"2010","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/21145398","citation_count":16,"is_preprint":false},{"pmid":"2896299","id":"PMC_2896299","title":"Chromosome aberrations associated with CAD gene amplification in Chinese hamster cultured cells.","date":"1988","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2896299","citation_count":16,"is_preprint":false},{"pmid":"16699957","id":"PMC_16699957","title":"The apoptotic endonuclease DFF40/CAD is inhibited by RNA, heparin and other polyanions.","date":"2006","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/16699957","citation_count":16,"is_preprint":false},{"pmid":"6180303","id":"PMC_6180303","title":"Properties of dispersed, highly repeated DNA within and near the hamster CAD gene.","date":"1982","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/6180303","citation_count":16,"is_preprint":false},{"pmid":"35622902","id":"PMC_35622902","title":"Persistent CAD activity in memory CD8+ T cells supports rRNA synthesis and ribosomal biogenesis required at rechallenge.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35622902","citation_count":16,"is_preprint":false},{"pmid":"33907891","id":"PMC_33907891","title":"Engineering the Cad pathway in Escherichia coli to produce glutarate from L-lysine.","date":"2021","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/33907891","citation_count":15,"is_preprint":false},{"pmid":"2885743","id":"PMC_2885743","title":"Transcriptional regulation of the human CAD gene during myeloid differentiation.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2885743","citation_count":15,"is_preprint":false},{"pmid":"23339695","id":"PMC_23339695","title":"CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.","date":"2012","source":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23339695","citation_count":14,"is_preprint":false},{"pmid":"17206380","id":"PMC_17206380","title":"Protein kinase A phosphorylation of the multifunctional protein CAD antagonizes activation by the MAP kinase cascade.","date":"2007","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17206380","citation_count":14,"is_preprint":false},{"pmid":"32021853","id":"PMC_32021853","title":"Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction.","date":"2020","source":"Journal of hepatocellular carcinoma","url":"https://pubmed.ncbi.nlm.nih.gov/32021853","citation_count":14,"is_preprint":false},{"pmid":"32207104","id":"PMC_32207104","title":"Computer-Aided Design and Manufacturing (CAD/CAM) for Bioprinting.","date":"2020","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/32207104","citation_count":13,"is_preprint":false},{"pmid":"33885177","id":"PMC_33885177","title":"PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.","date":"2021","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33885177","citation_count":13,"is_preprint":false},{"pmid":"29310573","id":"PMC_29310573","title":"Association of rs662799 in APOA5 with CAD in Chinese Han population.","date":"2018","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29310573","citation_count":13,"is_preprint":false},{"pmid":"18291523","id":"PMC_18291523","title":"Endosomal colocalization of melanocortin-3 receptor and beta-arrestins in CAD cells with altered modification of AKT/PKB.","date":"2008","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/18291523","citation_count":12,"is_preprint":false},{"pmid":"28835968","id":"PMC_28835968","title":"PON1 L55M and Q192R gene polymorphisms and CAD risks in patients with hyperlipidemia : Clinical study of possible associations.","date":"2017","source":"Herz","url":"https://pubmed.ncbi.nlm.nih.gov/28835968","citation_count":12,"is_preprint":false},{"pmid":"24316846","id":"PMC_24316846","title":"Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD.","date":"2013","source":"Acta crystallographica. Section F, Structural biology and crystallization communications","url":"https://pubmed.ncbi.nlm.nih.gov/24316846","citation_count":12,"is_preprint":false},{"pmid":"17254022","id":"PMC_17254022","title":"Extracellular cAMP inhibits D1 dopamine receptor expression in CAD catecholaminergic cells via A2a adenosine receptors.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17254022","citation_count":12,"is_preprint":false},{"pmid":"12441163","id":"PMC_12441163","title":"Adrenergic differentiation and SSR2a receptor expression in CAD-cells cultured in serum-free medium.","date":"2003","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/12441163","citation_count":11,"is_preprint":false},{"pmid":"34371647","id":"PMC_34371647","title":"CAD Genes: Genome-Wide Identification, Evolution, and Their Contribution to Lignin Biosynthesis in Pear (Pyrus bretschneideri).","date":"2021","source":"Plants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34371647","citation_count":11,"is_preprint":false},{"pmid":"36289038","id":"PMC_36289038","title":"A Deep Learning-Based Computer Aided Detection (CAD) System for Difficult-to-Detect Brain Metastases.","date":"2022","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/36289038","citation_count":11,"is_preprint":false},{"pmid":"33387146","id":"PMC_33387146","title":"The role of the DFF40/CAD endonuclease in genomic stability.","date":"2021","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/33387146","citation_count":10,"is_preprint":false},{"pmid":"33033488","id":"PMC_33033488","title":"Identification of Potential Biomarkers for CAD Using Integrated Expression and Methylation Data.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33033488","citation_count":10,"is_preprint":false},{"pmid":"34884720","id":"PMC_34884720","title":"Homo- and Hetero-Dimers of CAD Enzymes Regulate Lignification and Abiotic Stress Response in Moso Bamboo.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34884720","citation_count":10,"is_preprint":false},{"pmid":"39414920","id":"PMC_39414920","title":"Elevated circulating LncRNA NORAD fosters endothelial cell growth and averts ferroptosis by modulating the miR-106a/CCND1 axis in CAD patients.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39414920","citation_count":10,"is_preprint":false},{"pmid":"16007468","id":"PMC_16007468","title":"Immunohistochemical characterisation of differentiated CAD cells: expression of peptides and chromogranins.","date":"2005","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16007468","citation_count":10,"is_preprint":false},{"pmid":"36671534","id":"PMC_36671534","title":"Complexed Crystal Structure of the Dihydroorotase Domain of Human CAD Protein with the Anticancer Drug 5-Fluorouracil.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36671534","citation_count":10,"is_preprint":false},{"pmid":"36672766","id":"PMC_36672766","title":"Identification and Functional Analysis of CAD Gene Family in Pomegranate (Punica granatum).","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36672766","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50115,"output_tokens":6554,"usd":0.124327,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15835,"output_tokens":6965,"usd":0.12665,"stage2_stop_reason":"end_turn"},"total_usd":0.250977,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Caspase-3 cleaves ICAD (inhibitor of CAD/DFF40) at two specific sites, inactivating its CAD-inhibitory function and thereby releasing active CAD to mediate internucleosomal DNA degradation during apoptosis. Site-directed mutagenesis of both caspase-3 cleavage sites in ICAD blocked DNA degradation in Jurkat cells treated with Fas ligand or staurosporine, even though caspase activity was retained.\",\n      \"method\": \"Site-directed mutagenesis of ICAD caspase-3 cleavage sites; stable transfection of Jurkat cells; apoptosis induction assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis confirmed cleavage sites, functional rescue experiment in cells, replicated across multiple apoptotic stimuli\",\n      \"pmids\": [\"9422513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of activated CAD/DFF40 reveals it forms a homodimer with a deep active-site crevice suited for cleaving internucleosomal linker DNA. ICAD/DFF45 sequesters the nonfunctional CAD monomer and can also disassemble the active dimer via its middle domain; caspase cleavage of ICAD releases CAD to self-assemble into the active dimer.\",\n      \"method\": \"X-ray crystallography of activated CAD/DFF40; biochemical dimer assembly/disassembly assays\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure combined with biochemical validation of dimer assembly mechanism\",\n      \"pmids\": [\"15149602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The N-terminal CAD domain of CAD/DFF40 adopts a ubiquitin superfold (one alpha-helix, five beta-strands) and binds tightly to the CAD domain of ICAD (Kd ~55 nM), indicating that this domain-domain interaction is critical for inhibition of DNase activity and for correct folding of CAD.\",\n      \"method\": \"Multi-dimensional NMR spectroscopy; surface plasmon resonance binding assay\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure determination plus quantitative binding measurement by SPR in single rigorous study\",\n      \"pmids\": [\"10764577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CAD/DFF40 is essential for oligonucleosomal DNA fragmentation and final nuclear condensation/fragmentation during apoptosis, but is dispensable for high-molecular-weight DNA cleavage and early-stage chromatin condensation, demonstrating the existence of one or more separate nucleases responsible for those earlier events.\",\n      \"method\": \"Gene knockout (CAD−/− DT40 chicken cells with full ORF deletion); apoptosis induction assays; DNA gel electrophoresis; nuclear morphology analysis\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with specific phenotypic readouts, replicated across multiple apoptotic stimuli\",\n      \"pmids\": [\"11577114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DFF40/CAD is a Mg2+-dependent endonuclease specific for double-stranded DNA that is optimally active at 50–125 mM K+ (matching apoptotic cytoplasmic ionic conditions), inhibited by Zn2+ and Cu2+, and active over pH 7.0–8.5. At high ionic strength the enzyme introduces single-strand nicks rather than double-strand breaks.\",\n      \"method\": \"In vitro endonuclease activity assays with purified DFF40/CAD across varying ionic conditions, divalent metals, and pH\",\n      \"journal\": \"Molecular and Cellular Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with systematic cofactor variation, single lab\",\n      \"pmids\": [\"11330826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DFF40/CAD exclusively cleaves double-stranded DNA and does not cleave single-stranded DNA, RNA, double-stranded RNA, or RNA-DNA heteroduplexes; non-substrate nucleic acids act as competitive inhibitors of dsDNA cleavage, suggesting they bind the enzyme's DNA-binding site.\",\n      \"method\": \"In vitro nuclease assays with synthetic single- and double-stranded ribo- and deoxyribo-oligonucleotides; in vivo apoptosis RNA degradation correlation\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic in vitro substrate specificity analysis with multiple substrate types, single lab\",\n      \"pmids\": [\"18283539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DFF40/CAD is inhibited by polyanions including RNA, single-stranded DNA, poly-glutamic acid, and heparin (nanomolar potency); these polyanions bind to positively charged surfaces formed by the alpha-4 helices of the DFF40/CAD homodimer, impairing dsDNA binding.\",\n      \"method\": \"In vitro nuclease inhibition assays with purified DFF40/CAD; structural mapping to homodimer surface\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro biochemical assay with structural interpretation, single lab, single method\",\n      \"pmids\": [\"16699957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIIA (CAD inhibitor that interacts with ASK1) binds directly to CAD and inhibits its nuclease activity without affecting caspase-3-mediated ICAD cleavage; CIIA also inhibits ASK1 oligomerization-dependent activation; antisense knockdown of endogenous CIIA promotes DNA fragmentation and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; in vitro nuclease activity assay; antisense knockdown in L929 cells; apoptosis assays\",\n      \"journal\": \"The Journal of Cell Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional nuclease assay plus knockdown, single lab\",\n      \"pmids\": [\"14557248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The dihydroorotase (DHO) domain of CAD is located at the extreme amino terminus of the polypeptide; it contains one tightly bound zinc atom per subunit that participates in catalysis; the isolated 44 kDa domain forms a concentration-dependent dimer–monomer equilibrium; chelating agents inhibit its activity.\",\n      \"method\": \"Controlled elastase proteolysis of CAD; atomic absorption spectrophotometry; 65Zn radiolabeling; hydrodynamic characterization; chelator inhibition assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical isolation, radioisotope confirmation of zinc content, multiple orthogonal methods\",\n      \"pmids\": [\"2871022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"The aspartate transcarbamylase (ATCase) domain of CAD is a distinct ~40 kDa structural domain released by early controlled proteolysis; it forms an oligomer of 2–3 subunits; its kinetic parameters (Km, Vmax) closely match those of intact CAD, but the isolated domain is less stable (half-life 10.6 h vs 60.2 h for intact CAD), indicating stabilizing interactions with adjacent domains.\",\n      \"method\": \"Controlled proteolysis; ion-exchange chromatography purification; SDS-PAGE; steady-state kinetics; thermal stability assay\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain isolation with rigorous kinetic and structural characterization, multiple orthogonal methods\",\n      \"pmids\": [\"6300078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Domain order in CAD is GLNase-CPSase-DHOase-ATCase (confirmed by antibody probing of limited proteolysis fragments, ruling out the previously proposed DHOase-GLNase-CPSase-ATCase order). Phosphorylation by cAMP-dependent protein kinase (PKA) at two sites (site 1 near C-terminal end of CPSase domain, site 2 unmapped) accelerates protease cleavage of CAD and abolishes the protective effect of UTP.\",\n      \"method\": \"Limited proteolysis with elastase/trypsin; immunoblotting with domain-specific antibodies; in vitro PKA phosphorylation; analytical isoelectric focusing of tryptic phosphopeptides\",\n      \"journal\": \"European Journal of Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (proteolysis mapping, domain antibodies, phosphopeptide analysis), rules out alternative model\",\n      \"pmids\": [\"3345746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CAD is predominantly cytosolic in mammalian cells with a punctate distribution suggesting association with subcellular structures, not uniformly soluble; it is largely excluded from the nucleus and not concentrated near mitochondria, indicating that the intermediate dihydroorotate diffuses freely rather than being channeled to the mitochondrial enzyme dihydroorotate dehydrogenase.\",\n      \"method\": \"Differential centrifugation fractionation; immunocytochemical localization (two methods); immunofluorescence microscopy in BHK cells\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent localization methods plus fractionation, single lab\",\n      \"pmids\": [\"2903106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MAP kinase (ERK1/2) phosphorylates CAD at Thr-456 to activate de novo pyrimidine biosynthesis; phospho-Thr-456 CAD is preferentially localized in the nucleus associated with insoluble nuclear substructures including the nuclear matrix. Nuclear import of CAD is not driven by MAP kinase phosphorylation itself. When CAD is excluded from the nucleus (NES-CAD construct), pyrimidine biosynthesis rate, nucleotide pools, and cell growth are each reduced (~21%, 36%, and 60% respectively), demonstrating that nuclear localization is required for optimal pathway activity.\",\n      \"method\": \"Cell fractionation; fluorescence microscopy; phospho-specific antibodies; Thr-456 mutagenesis; NLS-CAD and NES-CAD fluorescent constructs; HPLC nucleotide pool measurement; growth rate assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (fractionation, imaging, mutagenesis, metabolic assays), functional consequence of localization demonstrated\",\n      \"pmids\": [\"15890648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CAD Thr-456 phosphorylation by MAP kinase (ERK1/2) activates pyrimidine biosynthesis; PKA phosphorylation of Ser-1406 antagonizes this by blocking ERK-mediated Thr-456 phosphorylation (and vice versa). Both MAP kinase and PKA form stable complexes with CAD, and the mutual antagonism results from steric interference by bound kinases. PKC (delta and epsilon isoforms) phosphorylates CAD at Ser-1873 and promotes MAP kinase phosphorylation of Thr-456 in a PKC-dependent manner; deletion of Ser-1873 abolishes PMA-induced Thr-456 phosphorylation.\",\n      \"method\": \"In vitro kinase assays with purified CAD and PKC isoforms; LC/MS phosphosite identification; PKC activator (PMA) and inhibitor treatments; Co-immunoprecipitation of kinase-CAD complexes; deletion mutagenesis\",\n      \"journal\": \"Molecular and Cellular Biochemistry / Frontiers in Bioscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assays plus mutagenesis plus in vivo pharmacological validation, multiple orthogonal approaches\",\n      \"pmids\": [\"17206380\", \"17485345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Oncogenic β-catenin transcriptionally upregulates AKT2, which then phosphorylates CAD at Ser-1406 and Ser-1859 to potentiate de novo pyrimidine synthesis, driving hepatocellular carcinoma proliferation. Inhibition of the β-catenin/AKT2/CAD axis preferentially suppressed β-catenin mutant cell proliferation and tumor formation.\",\n      \"method\": \"Untargeted metabolomics; reporter gene assays; phospho-site identification by mass spectrometry; siRNA knockdown; mouse liver tumor models; pharmacological inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences USA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomics plus mechanistic phosphorylation mapping plus in vivo mouse models, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36122209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CAD de novo pyrimidine synthesis is allosterically regulated during the cell cycle by UTP binding to two Animalia-specific loops in the CAD allosteric domain; these loops sense and bind UTP (a CAD allosteric inhibitor), and a signal transmission loop controls formation of the substrate channel to regulate CAD activity. Mutation scanning established that allostery is the primary mechanism of cell-cycle-phase-dependent CAD activity change.\",\n      \"method\": \"Cell synchronization + metabolomics; systematic mutational scanning; structural modeling based on mitochondrial CPS homologue; in cellulo CAD activity assays\",\n      \"journal\": \"Nature Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutational scanning combined with structural modelling and metabolomics in synchronized cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36747088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Adenovirus precursor terminal protein (pTP) physically binds to CAD at active viral DNA replication sites on the nuclear matrix; pTP-CAD complexes are immunoprecipitable from cell extracts and from in vitro-translated proteins; both pTP and CAD co-localize in nuclear foci that also contain sites of active DNA replication (BrdU incorporation).\",\n      \"method\": \"Far-Western blotting; amino acid sequencing; co-immunoprecipitation from cell extracts; in vitro translation co-IP; confocal co-localization immunofluorescence\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and in vitro binding plus co-localization, single lab\",\n      \"pmids\": [\"9525610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ebola virus nucleoprotein NP directly interacts with CAD and recruits it into viral inclusion bodies; this recruitment depends on the glutaminase (GLN) domain of CAD. siRNA knockdown of CAD impairs both EBOV genome replication and transcription; substrate rescue experiments demonstrate that CAD's pyrimidine synthesis function is required for these processes.\",\n      \"method\": \"Co-immunoprecipitation; co-immunofluorescence; siRNA knockdown; reverse genetics life-cycle modelling; substrate (uridine) rescue experiments; GLN-domain deletion constructs\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus domain mapping plus functional knockdown with rescue, single lab\",\n      \"pmids\": [\"32370067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CAD (the pyrimidine biosynthesis enzyme) binds directly to NOD2 and inhibits NOD2-dependent NF-κB and p38 MAPK activation as well as intracellular killing of Salmonella; reduction of CAD expression or pharmacological CAD inhibition enhances NOD2 antibacterial signaling function, identifying CAD as a negative regulator of NOD2.\",\n      \"method\": \"Immunoprecipitation-coupled mass spectrometry identification of NOD2 interactome; co-immunoprecipitation; reporter gene assays; gentamicin protection assay; siRNA knockdown; CAD inhibitor treatment\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification confirmed by Co-IP and functional knockdown/inhibitor assays, single lab\",\n      \"pmids\": [\"22387394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CAD (pyrimidine biosynthesis enzyme) physically interacts with the androgen receptor (AR) in prostate tumor cells and promotes AR nuclear translocation and transcriptional activity, revealing a non-metabolic function of CAD in nuclear receptor signaling.\",\n      \"method\": \"AR immunopurification from xenograft tumors; co-immunoprecipitation in prostate cell lines; AR transcriptional reporter assays; nuclear localization imaging\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional transcriptional assay plus localization, single lab\",\n      \"pmids\": [\"21982950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Executioner caspase activation of CAD/DFF40 endonuclease is essential for TRAIL-induced mutagenesis and for vincristine-induced mutagenesis in surviving cells; this identifies a non-apoptotic, pro-mutagenic role for caspase-activated CAD.\",\n      \"method\": \"Genetic knockout/inhibition of executioner caspases and CAD; mutation frequency assays in surviving cells after TRAIL or vincristine treatment\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic loss-of-function with specific mutagenesis phenotype readout, single lab\",\n      \"pmids\": [\"28981092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CAD activity persists in memory CD8+ T cells after initial activation (sustained phosphorylation in mTORC1-dependent manner) and supports ongoing de novo pyrimidine synthesis required for pre-rRNA synthesis and ribosomal biogenesis; CAD inhibition reduces ribosomal protein levels and diminishes the speed and magnitude of cytokine production upon rechallenge, while CAD overexpression enhances recall responses.\",\n      \"method\": \"CAD activity/phosphorylation assays in resting vs. activated T cells; metabolomics; CAD inhibitor treatment; CAD overexpression; pre-rRNA and ribosomal protein quantification; cytokine production assays\",\n      \"journal\": \"Science Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus overexpression with multiple functional readouts, single lab\",\n      \"pmids\": [\"35622902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Crystal structures of the dihydroorotase domain of human CAD (huDHOase) complexed with 5-fluorouracil (1.97 Å) and with malate reveal that, unlike the E. coli DHOase, huDHOase binds non-substrate ligands in a loop-in mode at the active site; site-directed mutagenesis and fluorescence quenching confirmed the binding interaction, identifying the dynamic active-site loop as a drug-targeting site.\",\n      \"method\": \"X-ray crystallography (1.97 Å); site-directed mutagenesis; fluorescence quenching binding assay\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure determination plus mutagenesis plus independent binding assay, single lab\",\n      \"pmids\": [\"36671534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Afatinib (EGFR-TKI) directly targets CAD, the key de novo pyrimidine biosynthesis enzyme, suppressing CD8+ T lymphocyte proliferation; this mechanism underlies afatinib-mediated immunosuppression distinct from its EGFR kinase inhibition.\",\n      \"method\": \"Biochemical target identification of afatinib binding to CAD; CD8+ T cell proliferation assays with afatinib; in vivo Lewis lung carcinoma and MC38 tumor models; tumor-infiltrating lymphocyte quantification\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical target identification plus functional in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"33771897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The ATCase domain of human CAD forms homotrimers in solution and crystallizes in space group P6322 (2.1 Å resolution), establishing the structural basis for CAD hexamer formation through ATCase trimer-of-trimers interactions.\",\n      \"method\": \"Recombinant domain expression in bacteria; gel filtration (homotrimer confirmation); X-ray crystallography (2.1 Å)\",\n      \"journal\": \"Acta Crystallographica Section F\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystallographic structure of isolated domain, preliminary diffraction data reported, single lab\",\n      \"pmids\": [\"24316846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR/Cas9 knockout of CAD in human cells confirmed that CAD enzymatic activity is required for cell survival in the absence of exogenous uridine; a complementation assay using transient transfection of recombinant CAD into knockout cells was validated as a reliable pathogenicity test for CAD missense variants.\",\n      \"method\": \"CRISPR/Cas9 gene knockout; uridine-dependent growth complementation assay; transient transfection of variant CAD constructs\",\n      \"journal\": \"Genetics in Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined metabolic phenotype, complementation assay validated across 34 variants in multiple labs/patients\",\n      \"pmids\": [\"32461667\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CAD is a ~250 kDa multienzymatic protein (organized GLNase-CPSase-DHOase-ATCase from N to C terminus) that hexamerizes to form a ~1.5 MDa particle catalyzing the first three rate-limiting steps of de novo pyrimidine biosynthesis; its activity is cell-cycle regulated by sequential phosphorylation—MAP kinase (ERK1/2) activates it at Thr-456 after nuclear import, PKA antagonizes this at Ser-1406/Ser-1859, and PKC delta/epsilon modulate ERK access via Ser-1873—while UTP allosterically inhibits it through Animalia-specific loops controlling a substrate channel; in apoptosis a completely separate ~40 kDa nuclease function (CAD/DFF40) is activated when caspase-3 cleaves its inhibitor ICAD, releasing active CAD homodimers that specifically cleave internucleosomal double-stranded DNA in a Mg2+-dependent manner to produce oligonucleosomal laddering and drive final chromatin condensation; beyond these canonical roles, CAD interacts with the androgen receptor to promote its nuclear translocation, with NOD2 to suppress antibacterial signaling, with Ebola NP to supply pyrimidines for viral replication, and is a direct target of the EGFR inhibitor afatinib, thereby suppressing T cell proliferation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CAD is a multienzymatic protein that catalyzes the first three rate-limiting steps of de novo pyrimidine biosynthesis through an N-to-C domain arrangement of GLNase-CPSase-DHOase-ATCase [#10], with the N-terminal dihydroorotase domain carrying a single catalytic zinc atom [#8] and the C-terminal ATCase domain forming homotrimers that provide the trimer-of-trimers interface underlying CAD oligomerization [#24]. Pathway flux is governed by sequential phosphorylation: ERK1/2 (MAP kinase) activates CAD at Thr-456 [#12, #13], an event antagonized by PKA phosphorylation at Ser-1406 through steric interference between stably bound kinases, while PKC delta/epsilon phosphorylation at Ser-1873 promotes ERK access [#13]; in tumors, oncogenic beta-catenin drives an AKT2-dependent CAD phosphorylation at Ser-1406/Ser-1859 to potentiate proliferation [#14]. Activation requires CAD to be imported into the nucleus, where phospho-Thr-456 CAD associates with the nuclear matrix and nuclear localization is needed for optimal pyrimidine synthesis, nucleotide pools, and growth [#12], and across the cell cycle activity is set allosterically by UTP binding to two Animalia-specific loops that gate the substrate channel [#15]. CAD enzymatic activity is essential for cell survival without exogenous uridine, and its complementation assay defines pathogenicity of disease-associated CAD missense variants [#25]. Entirely separately, CAD also denotes the apoptotic endonuclease CAD/DFF40, held inactive by its inhibitor ICAD/DFF45 until caspase-3 cleaves ICAD to release CAD homodimers [#0, #1] that, as a Mg2+-dependent enzyme acting specifically on double-stranded DNA, cleave internucleosomal linker DNA to drive oligonucleosomal laddering and final chromatin condensation [#3, #4]. Beyond these roles, CAD physically engages partners that co-opt its pyrimidine output or non-metabolic activity, including the androgen receptor to promote its nuclear translocation [#19], NOD2 to suppress antibacterial NF-kappaB/p38 signaling [#18], and Ebola virus NP, which recruits CAD via its glutaminase domain to supply pyrimidines for viral replication [#17].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing that CAD's catalytic activities reside in separable, autonomously folding domains was the first step in defining how one polypeptide performs multiple enzymatic steps.\",\n      \"evidence\": \"Controlled proteolysis and kinetic/thermal characterization of the released ~40 kDa ATCase domain\",\n      \"pmids\": [\"6300078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish full domain order\", \"Stabilizing inter-domain contacts inferred from stability differences, not structurally resolved\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Localizing the dihydroorotase domain to the extreme N-terminus and identifying its catalytic zinc clarified the chemistry of one CAD active site.\",\n      \"evidence\": \"Elastase proteolysis, 65Zn radiolabeling, atomic absorption, and chelator inhibition of the isolated 44 kDa domain\",\n      \"pmids\": [\"2871022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism of zinc not resolved at atomic level here\", \"Did not address regulation of the domain in intact CAD\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Resolving the definitive GLNase-CPSase-DHOase-ATCase domain order and demonstrating PKA phosphorylation that abolishes UTP protection linked CAD architecture to its regulation.\",\n      \"evidence\": \"Limited proteolysis with domain-specific antibodies plus in vitro PKA phosphorylation and phosphopeptide mapping\",\n      \"pmids\": [\"3345746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Second PKA phosphosite unmapped\", \"Physiological consequence of PKA phosphorylation on flux not measured\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Subcellular localization addressed whether CAD channels its intermediate to mitochondria, showing it is cytosolic and punctate rather than mitochondria-associated.\",\n      \"evidence\": \"Differential centrifugation and dual immunocytochemical localization in BHK cells\",\n      \"pmids\": [\"2903106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve the nature of the punctate structures\", \"Predates discovery of activation-dependent nuclear import\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identifying caspase-3 cleavage of ICAD as the trigger that releases CAD/DFF40 explained how apoptotic DNA fragmentation is switched on.\",\n      \"evidence\": \"Site-directed mutagenesis of ICAD cleavage sites and rescue in Fas/staurosporine-treated Jurkat cells\",\n      \"pmids\": [\"9422513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of CAD activation\", \"Did not distinguish CAD's contribution from other apoptotic nucleases\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that CAD binds adenovirus pTP at nuclear-matrix replication sites was the first link between CAD and viral DNA replication machinery.\",\n      \"evidence\": \"Far-Western, reciprocal Co-IP, and confocal co-localization with BrdU incorporation sites\",\n      \"pmids\": [\"9525610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional requirement of CAD for viral replication not tested\", \"Which CAD function (metabolic vs structural) is involved unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defining the CAD-domain ubiquitin superfold and its tight binding to ICAD established the molecular basis of nuclease inhibition and folding.\",\n      \"evidence\": \"Multidimensional NMR structure and SPR binding measurement (Kd ~55 nM)\",\n      \"pmids\": [\"10764577\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture the full active dimer\", \"Mechanism coupling inhibition to folding inferred, not directly observed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Genetic knockout assigned CAD/DFF40 specifically to oligonucleosomal fragmentation and late nuclear condensation, revealing distinct earlier-acting nucleases.\",\n      \"evidence\": \"CAD-/- DT40 cells with full ORF deletion, DNA electrophoresis, and nuclear morphology across apoptotic stimuli\",\n      \"pmids\": [\"11577114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the high-molecular-weight cleavage nucleases not established\", \"Did not address non-apoptotic functions\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Biochemical reconstitution defined CAD/DFF40 as a Mg2+-dependent dsDNA endonuclease tuned to apoptotic ionic conditions.\",\n      \"evidence\": \"In vitro endonuclease assays varying K+, divalent metals, and pH with purified enzyme\",\n      \"pmids\": [\"11330826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single lab\", \"In vitro conditions may not fully recapitulate chromatin context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying CIIA as a direct CAD-binding inhibitor that acts downstream of ICAD cleavage revealed an additional layer of nuclease control.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro nuclease assay, and antisense knockdown in L929 cells\",\n      \"pmids\": [\"14557248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab without structural mapping of the CIIA-CAD interface\", \"Physiological dominance over ICAD regulation unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The activated CAD/DFF40 crystal structure showed it is a homodimer with a linker-DNA-cleaving crevice and clarified how ICAD assembles or disassembles it.\",\n      \"evidence\": \"X-ray crystallography of activated CAD/DFF40 with biochemical dimer assembly/disassembly assays\",\n      \"pmids\": [\"15149602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture DNA-bound state\", \"Catalytic mechanism at the metal site not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing that ERK-mediated Thr-456 phosphorylation activates CAD and that nuclear localization is required for optimal pathway flux connected signaling, localization, and metabolic output.\",\n      \"evidence\": \"Phospho-specific antibodies, Thr-456 mutagenesis, NLS/NES-CAD constructs, HPLC nucleotide pools, and growth assays\",\n      \"pmids\": [\"15890648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism driving CAD nuclear import not identified\", \"Nature of nuclear-matrix association unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapping polyanion inhibition to the alpha-4 helices of the DFF40 dimer explained how RNA and other polyanions block dsDNA binding.\",\n      \"evidence\": \"In vitro nuclease inhibition assays with structural surface mapping\",\n      \"pmids\": [\"16699957\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single method\", \"Physiological relevance of polyanion inhibition in vivo not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating exclusive dsDNA cleavage with competitive inhibition by other nucleic acids refined CAD/DFF40 substrate specificity.\",\n      \"evidence\": \"In vitro nuclease assays with synthetic ribo/deoxyribo oligonucleotides plus apoptosis RNA correlation\",\n      \"pmids\": [\"18283539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not structurally define the DNA-binding site\", \"In vivo competition by cellular RNA not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing reciprocal antagonism among ERK, PKA, and PKC at distinct CAD phosphosites defined the integrated kinase code controlling pyrimidine synthesis.\",\n      \"evidence\": \"In vitro kinase assays, LC/MS phosphosite mapping, PMA/inhibitor treatments, kinase-CAD Co-IP, and deletion mutagenesis\",\n      \"pmids\": [\"17206380\", \"17485345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each phosphosite to in vivo flux not fully resolved\", \"Structural basis of steric kinase interference inferred, not visualized\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linking CAD to androgen receptor nuclear translocation revealed a non-metabolic function in nuclear receptor signaling.\",\n      \"evidence\": \"AR immunopurification from xenografts, Co-IP in prostate cells, AR reporter assays, and localization imaging\",\n      \"pmids\": [\"21982950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab without structural interaction mapping\", \"Whether CAD enzymatic activity is required for AR effect untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying CAD as a direct NOD2 binder that suppresses antibacterial signaling assigned it a negative-regulatory role in innate immunity.\",\n      \"evidence\": \"IP-MS interactome, Co-IP, NF-kappaB/p38 reporters, gentamicin protection, siRNA, and CAD inhibitor treatment\",\n      \"pmids\": [\"22387394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Whether the inhibitory effect depends on CAD catalytic activity not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Solving the human ATCase domain homotrimer structure established the structural basis for CAD hexamer assembly.\",\n      \"evidence\": \"Recombinant domain expression, gel filtration, and X-ray crystallography at 2.1 Å\",\n      \"pmids\": [\"24316846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Isolated domain only; full-length hexamer not solved\", \"Preliminary diffraction data, single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that caspase-activated CAD/DFF40 drives mutagenesis in surviving cells revealed a non-apoptotic, pro-mutagenic role.\",\n      \"evidence\": \"Genetic loss-of-function of executioner caspases and CAD with mutation-frequency assays after TRAIL or vincristine\",\n      \"pmids\": [\"28981092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism by which sublethal CAD activity produces mutations not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Ebola NP was shown to recruit CAD via its glutaminase domain to supply pyrimidines required for viral replication and transcription.\",\n      \"evidence\": \"Co-IP, co-immunofluorescence, siRNA knockdown, reverse genetics, GLN-domain deletion, and uridine rescue\",\n      \"pmids\": [\"32370067\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural basis of NP-GLN domain binding unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR knockout established CAD enzymatic activity as essential without exogenous uridine and validated a complementation assay for variant pathogenicity, linking CAD to human disease genetics.\",\n      \"evidence\": \"CRISPR/Cas9 knockout, uridine-dependent growth complementation, and transient transfection of variant constructs across 34 variants\",\n      \"pmids\": [\"32461667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not enumerate the clinical disease phenotype mechanistically\", \"Variant effects on specific catalytic steps not dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying CAD as a direct afatinib target explained an EGFR-kinase-independent immunosuppressive effect on CD8+ T cells.\",\n      \"evidence\": \"Biochemical target identification, T cell proliferation assays, and in vivo LLC/MC38 tumor models with TIL quantification\",\n      \"pmids\": [\"33771897\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Afatinib binding site on CAD not structurally defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining a beta-catenin/AKT2/CAD phosphorylation axis at Ser-1406/Ser-1859 linked oncogenic signaling to pyrimidine-driven hepatocellular carcinoma growth.\",\n      \"evidence\": \"Untargeted metabolomics, reporter assays, MS phosphosite mapping, siRNA, mouse liver tumor models, and pharmacological inhibition\",\n      \"pmids\": [\"36122209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with ERK/PKA phosphorylation not resolved\", \"Whether AKT2 acts on the same residues across tissues untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating sustained mTORC1-dependent CAD activity in memory CD8+ T cells coupled pyrimidine synthesis to ribosome biogenesis and recall responses.\",\n      \"evidence\": \"CAD phosphorylation/activity assays, metabolomics, inhibition, overexpression, pre-rRNA and ribosomal protein quantification, and cytokine assays\",\n      \"pmids\": [\"35622902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct connection between pyrimidine pools and rRNA synthesis mechanistically partial\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying UTP-sensing Animalia-specific allosteric loops controlling the substrate channel established allostery as the primary driver of cell-cycle-dependent CAD activity.\",\n      \"evidence\": \"Cell synchronization with metabolomics, systematic mutational scanning, structural modeling, and in cellulo activity assays\",\n      \"pmids\": [\"36747088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allosteric mechanism modeled rather than crystallographically resolved in full-length CAD\", \"Interplay between allostery and phosphorylation not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Crystal structures of the human DHOase domain with non-substrate ligands revealed a loop-in binding mode distinct from E. coli, identifying a druggable active-site loop.\",\n      \"evidence\": \"X-ray crystallography at 1.97 Å with 5-fluorouracil and malate, mutagenesis, and fluorescence quenching\",\n      \"pmids\": [\"36671534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Drug efficacy of loop targeting not demonstrated in cells\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the metabolic kinase/allosteric regulatory network, the nuclear-import requirement, and the diverse partner-driven moonlighting functions are integrated within the assembled CAD hexamer in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No full-length hexamer structure linking domains and regulatory sites\", \"Mechanism of activation-dependent nuclear import unidentified\", \"Whether moonlighting interactions require catalytic activity largely untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [8, 22]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [9, 24]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 25]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [12, 15]}\n    ],\n    \"complexes\": [\"CAD hexamer\", \"CAD/DFF40-ICAD/DFF45 complex\"],\n    \"partners\": [\"ICAD\", \"CIIA\", \"NOD2\", \"AR\", \"AKT2\", \"Ebola NP\", \"adenovirus pTP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}